SHANGHAI (Reuters) -U.S. President Donald Trump on Thursday unveiled a 100% tariff on imports of branded drugs from October 1, unless their producers had already broken ground on U.S. manufacturing plants.

The European Union and Japan expressed confidence on Friday that they had secured limits on U.S. tariffs on pharmaceuticals.

Below are some of the patented medicines from Asian and European drugmakers imported into the U.S. from overseas manufacturing sites in countries including China, Switzerland, Japan, Belgium and France, according to analysts and drugmaker statements.

Lenvima

Japan’s Eisai’s cancer drug Lenvima is manufactured in Japan, J.P.Morgan wrote in a recent note. Its US sales for the fiscal year ending March 31, 2025 were 229.6 billion yen ($1.53 billion).

The company’s

See Full Page